We are live on ! Find out more
VEA

Virtus ETF Advisers Portfolio holdings

AUM $215M
1-Year Est. Return 53.68%
This Fund
S&P 500
This Quarter Est. Return
-14.02%
1 Year Est. Return
+53.68%
3 Year Est. Return
+121.72%
5 Year Est. Return
+144.54%
10 Year Est. Return
+633.35%
AUM
$270M
AUM Growth
+$46.4M
Cap. Flow
+$86.8M
Cap. Flow %
32.16%
Top 10 Hldgs %
7.48%
Holding
501
New
128
Increased
202
Reduced
102
Closed
67

Top Buys

Rank Stock Value
1
O icon
Realty Income
O
+$931K
2
SKM icon
SK Telecom
SKM
+$871K
3
MRNA icon
Moderna
MRNA
+$825K
4
COP icon
ConocoPhillips
COP
+$786K
5
PXD
Pioneer Natural Resource Co.
PXD
+$785K

Top Sells

Rank Stock Value
1
AEM icon
Agnico Eagle Mines
AEM
+$1.83M
2
BPMP
BP Midstream Partners LP Common Units representing Limited Partner Interests
BPMP
+$1.76M
3
MOS icon
The Mosaic Company
MOS
+$928K
4
STR
Sitio Royalties
STR
+$559K
5
GFI icon
Gold Fields
GFI
+$512K

Sector Composition

Rank Sector Weight
1 Real Estate 18.55%
2 Healthcare 17.07%
3 Materials 11.98%
4 Financials 11.43%
5 Energy 8.64%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KDNY
401
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$113K 0.04%
6,441
-4,095
-39% -$64.3K
PTGX icon
402
Protagonist Therapeutics
PTGX
$8.77B
$112K 0.04%
14,129
+8,913
+171% +$108K
ARQT icon
403
Arcutis Biotherapeutics
ARQT
$3.53B
$111K 0.04%
5,232
-5,127
-49% -$105K
CGEM icon
404
Cullinan Oncology
CGEM
$1.1B
$111K 0.04%
8,620
-1,321
-13% -$15K
FHTX icon
405
Foghorn Therapeutics
FHTX
$301M
$111K 0.04%
+8,198
New +$106K
XENE icon
406
Xenon Pharmaceuticals
XENE
$6.35B
$111K 0.04%
3,643
-2,435
-40% -$73.6K
AVIR icon
407
Atea Pharmaceuticals
AVIR
$390M
$110K 0.04%
15,548
-3,785
-20% -$25.8K
CRBU icon
408
Caribou Biosciences
CRBU
$160M
$110K 0.04%
20,215
+10,823
+115% +$82.7K
KOD icon
409
Kodiak Sciences
KOD
$2.66B
$110K 0.04%
14,453
+12,551
+660% +$88.2K
MORF
410
DELISTED
Morphic Holding, Inc. Common Stock
MORF
$109K 0.04%
5,027
+1,534
+44% +$42.8K
RETA
411
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
$109K 0.04%
3,579
-1,785
-33% -$53.3K
IMGO
412
DELISTED
Imago BioSciences, Inc. Common stock
IMGO
$109K 0.04%
8,134
-426
-5% -$6.76K
CRSP icon
413
CRISPR Therapeutics
CRSP
$4.63B
$108K 0.04%
1,784
-297
-14% -$17.5K
DSGN icon
414
Design Therapeutics
DSGN
$749M
$108K 0.04%
+7,716
New +$104K
MDGL icon
415
Madrigal Pharmaceuticals
MDGL
$12.8B
$108K 0.04%
1,504
-635
-30% -$46.7K
MGTX icon
416
MeiraGTx Holdings
MGTX
$1.15B
$108K 0.04%
14,264
+6,685
+88% +$64.9K
RPTX
417
DELISTED
Repare Therapeutics
RPTX
$106K 0.04%
7,586
-305
-4% -$3.59K
NGM
418
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
$106K 0.04%
8,263
-519
-6% -$7.19K
ISEE
419
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$106K 0.04%
10,997
+268
+2% +$3.36K
KROS icon
420
Keros Therapeutics
KROS
$205M
$105K 0.04%
3,793
+568
+18% +$24.9K
NKTX icon
421
Nkarta
NKTX
$164M
$105K 0.04%
8,514
-3,612
-30% -$47.4K
CVAC
422
DELISTED
CureVac
CVAC
$104K 0.04%
7,676
+3,648
+91% +$60.3K
CYTK icon
423
Cytokinetics
CYTK
$11B
$104K 0.04%
2,647
-1,529
-37% -$61.6K
AMRS
424
DELISTED
Amyris Inc.
AMRS
$104K 0.04%
56,359
+26,593
+89% +$78.3K
SRRA
425
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$104K 0.04%
+1,888
New +$99.1K
15 16
17
18 19

Similar funds

NCM
NEXTBio Capital Management Menlo Park, California $215M AUM
SSA
SSA Swiss Advisors Zurich $216M AUM 17.86% 1-Year Est. Return
LIWM
Long Island Wealth Management Melville, New York $216M AUM 14.59% 1-Year Est. Return
VFG
V2 Financial group Naperville, Illinois $215M AUM 15.18% 1-Year Est. Return
IAM
Impala Asset Management Palm Beach, Florida $215M AUM 86.77% 1-Year Est. Return
1M
1248 Management Kansas City, Missouri $216M AUM 12.29% 1-Year Est. Return
GC
GatePass Capital Independence, Ohio $214M AUM 29.83% 1-Year Est. Return
ALS
Andrew L. Share $214M AUM 14.75% 1-Year Est. Return

Virtus ETF Advisers's Q2 2022 Portfolio in Review

As of Q2 2022, Virtus ETF Advisers held 501 positions worth $270M, up 21% from $223M the previous quarter. Its ten largest holdings account for 7.5% of the portfolio.

Virtus ETF Advisers deployed $86.8M of net new capital in Q2 2022, opening 128 new positions and adding to 202 existing holdings. Its largest new stake was ConocoPhillips: 7,627 shares worth $685K.

By sector, the portfolio is most concentrated in Real Estate at 19% of assets, down from 20% a quarter earlier, followed by Healthcare and Materials.

On the sell side, the largest reduction was Agnico Eagle Mines, an estimated $1.83M trimmed.

  • Virtus ETF Advisers's largest Q2 2022 buy was ConocoPhillips: 7,627 shares worth $685K.
  • Virtus ETF Advisers added most to Realty Income in Q2 2022, an estimated $931K increase.
  • Virtus ETF Advisers's biggest Q2 2022 reduction was Agnico Eagle Mines, cutting an estimated $1.83M.
  • Virtus ETF Advisers fully exited BP Midstream Partners LP Common Units representing Limited Partner Interests in Q2 2022, selling an estimated $1.76M.
  • Virtus ETF Advisers's ten largest holdings make up 7.5% of its $270M portfolio in Q2 2022.
  • Virtus ETF Advisers opened 128 new positions and closed 67 in Q2 2022.
  • Virtus ETF Advisers's portfolio value rose 21% quarter-over-quarter to $270M.

Based on Virtus ETF Advisers's 13F filing for Q2 2022, filed 12 Aug 2022.